Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONVAC-C electroporation plus standard of care in treatment-naive chronic hepatitis C genotype 1
2010-022960-10Phase 2Active
- Sponsor
- ChronTech Pharma AB
- Start
- Nov 2010
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis C virus infection comparing CHRONVAC-C plus electroporation followed by standard of care with Standard of care control (2 arms). Primary endpoint: HCV-RNA kinetics. Started Nov 2010; status: active.
02
Drugs
chronvac-c
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-022960-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022960-10.